



July 10, 2017

Endologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference

IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Canaccord Genuity 37th Annual Growth Conference at 2:30 p.m. ET on Wednesday, August 9, 2017 in Boston, MA.

A live webcast of the presentation will be accessible through the "Investors" section of the Company's website at www.endologix.com and will be available for replay following the event.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. For more information, visit www.endologix.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170710005977/en/>

INVESTORS:

Endologix, Inc.

Vaseem Mahboob, CFO, 949-595-7200

Source: Endologix, Inc.

News Provided by Acquire Media